1
|
León K, García-Martínez K, Carmenate T, Rojas G. Combining computational and experimental biology to develop therapeutically valuable IL2 muteins. Semin Oncol 2018; 45:95-104. [PMID: 30318089 DOI: 10.1053/j.seminoncol.2018.04.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 03/28/2018] [Accepted: 04/20/2018] [Indexed: 01/23/2023]
Abstract
High-dose IL2, first approved in 1992, has been used in the treatment of advanced renal cell carcinoma and melanoma. In these indications, IL2 induces long lasting objective responses in 5% to 20% of patients. However, toxicity and the unexpected expansion of regulatory T cells (Tregs) have limited its practical use and therapeutic impact, respectively. At the Center of Molecular Immunology in Havana, Cuba, a project was launched in 2005 to rationally design IL2 muteins that could be deployed in the therapy of cancer. The basic goal was to uncouple the pleiotropic effect of IL2 on different immune T cells, to obtain a mutein with a therapeutic index that was better than that achieved with wild type (wt) IL2. Using a combination of computational and experimental biology approaches, we predicted and developed two novel IL2 muteins with therapeutic potential. The first, designated no-alpha mutein, is an agonist of IL2R signaling with a reduced ability to expand Treg in vivo. In mice, the no-alpha mutein IL2 has higher antitumor activity and lower toxicity than wt IL2. It represents a potential best-in-class drug that has begun phase I/II clinical trials in solid tumors. The second, designated no-gamma mutein, is an antagonist of IL2R signaling, with some preferential affinity for Tregs. This mutein has antitumor activity in mice that likely derives from its ability to reduce Treg accumulation in vivo. It represents a first-in-class drug that offers a novel strategy to inhibit Treg activity in vivo.
Collapse
Affiliation(s)
- Kalet León
- Center of Molecular Immunology (CIM), Havana, Cuba.
| | | | | | | |
Collapse
|
2
|
Carmenate T, Ortíz Y, Enamorado M, García-Martínez K, Avellanet J, Moreno E, Graça L, León K. Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells. THE JOURNAL OF IMMUNOLOGY 2018; 200:3475-3484. [PMID: 29618524 DOI: 10.4049/jimmunol.1700433] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 03/13/2018] [Indexed: 01/06/2023]
Abstract
IL-2 is critical for peripheral tolerance mediated by regulatory T (Treg) cells, which represent an obstacle for effective cancer immunotherapy. Although IL-2 is important for effector (E) T cell function, it has been hypothesized that therapies blocking IL-2 signals weaken Treg cell activity, promoting immune responses. This hypothesis has been partially tested using anti-IL-2 or anti-IL-2R Abs with antitumor effects that cannot be exclusively attributed to lack of IL-2 signaling in vivo. In this work, we pursued an alternative strategy to block IL-2 signaling in vivo, taking advantage of the trimeric structure of the IL-2R. We designed an IL-2 mutant that conserves the capacity to bind to the αβ-chains of the IL-2R but not to the γc-chain, thus having a reduced signaling capacity. We show our IL-2 mutein inhibits IL-2 Treg cell-dependent differentiation and expansion. Moreover, treatment with IL-2 mutein reduces Treg cell numbers and impairs tumor growth in mice. A mathematical model was used to better understand the effect of the mutein on Treg and E T cells, suggesting suitable strategies to improve its design. Our results show that it is enough to transiently inhibit IL-2 signaling to bias E and Treg cell balance in vivo toward immunity.
Collapse
Affiliation(s)
| | - Yaquelín Ortíz
- Centro de Inmunología Molecular, 16040 Havana, Cuba; and
| | | | | | | | - Ernesto Moreno
- Centro de Inmunología Molecular, 16040 Havana, Cuba; and
| | - Luis Graça
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal
| | - Kalet León
- Centro de Inmunología Molecular, 16040 Havana, Cuba; and
| |
Collapse
|
3
|
Mathematical Models for Immunology: Current State of the Art and Future Research Directions. Bull Math Biol 2016; 78:2091-2134. [PMID: 27714570 PMCID: PMC5069344 DOI: 10.1007/s11538-016-0214-9] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 09/26/2016] [Indexed: 01/01/2023]
Abstract
The advances in genetics and biochemistry that have taken place over the last 10 years led to significant advances in experimental and clinical immunology. In turn, this has led to the development of new mathematical models to investigate qualitatively and quantitatively various open questions in immunology. In this study we present a review of some research areas in mathematical immunology that evolved over the last 10 years. To this end, we take a step-by-step approach in discussing a range of models derived to study the dynamics of both the innate and immune responses at the molecular, cellular and tissue scales. To emphasise the use of mathematics in modelling in this area, we also review some of the mathematical tools used to investigate these models. Finally, we discuss some future trends in both experimental immunology and mathematical immunology for the upcoming years.
Collapse
|
4
|
Morel PA, Faeder JR, Hawse WF, Miskov-Zivanov N. Modeling the T cell immune response: a fascinating challenge. J Pharmacokinet Pharmacodyn 2014; 41:401-13. [PMID: 25155903 PMCID: PMC4210366 DOI: 10.1007/s10928-014-9376-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Accepted: 08/13/2014] [Indexed: 12/11/2022]
Abstract
The immune system is designed to protect the organism from infection and to repair damaged tissue. An effective response requires recognition of the threat, the appropriate effector mechanism to clear the pathogen and a return to homeostasis with minimal damage to self-tissues. T cells play a central role in orchestrating the immune response at all stages of the response and have been the subject of intense study by both experimental immunologists and modelers. This review examines some of the more critical questions in T cell biology and describes the latest attempts to address those questions using approaches that combine mathematical modeling and experiments.
Collapse
Affiliation(s)
- Penelope A Morel
- Departments of Immunology, University of Pittsburgh, 200 Lothrop Street, BST E1055, Pittsburgh, PA, 15261, USA,
| | | | | | | |
Collapse
|
5
|
León K, García-Martínez K, Carmenate T. Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics. Front Immunol 2013; 4:439. [PMID: 24376444 PMCID: PMC3858650 DOI: 10.3389/fimmu.2013.00439] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2013] [Accepted: 11/24/2013] [Indexed: 01/28/2023] Open
Abstract
Several reports in the literature have drawn a complex picture of the effect of treatments aiming to modulate IL2 activity in vivo. They seem to promote either immunity or tolerance, probably depending on the specific context, dose, and timing of their application. Such complexity might derive from the pleiotropic role of IL2 in T cell dynamics. To theoretically address the latter possibility, our group has developed several mathematical models for Helper, Regulatory, and Memory T cell population dynamics, which account for most well-known facts concerning their relationship with IL2. We have simulated the effect of several types of therapies, including the injection of: IL2; antibodies anti-IL2; IL2/anti-IL2 immune-complexes; and mutant variants of IL2. We studied the qualitative and quantitative conditions of dose and timing for these treatments which allow them to potentiate either immunity or tolerance. Our results provide reasonable explanations for the existent pre-clinical and clinical data, predict some novel treatments, and further provide interesting practical guidelines to optimize the future application of these types of treatments.
Collapse
Affiliation(s)
- Kalet León
- Systems Biology Department, Center of Molecular Immunology , Habana , Cuba
| | | | - Tania Carmenate
- Systems Biology Department, Center of Molecular Immunology , Habana , Cuba
| |
Collapse
|
6
|
Caridade M, Graca L, Ribeiro RM. Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models. Front Immunol 2013; 4:378. [PMID: 24302924 PMCID: PMC3831161 DOI: 10.3389/fimmu.2013.00378] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 11/03/2013] [Indexed: 12/29/2022] Open
Abstract
To maintain immunological balance the organism has to be tolerant to self while remaining competent to mount an effective immune response against third-party antigens. An important mechanism of this immune regulation involves the action of regulatory T-cell (Tregs). In this mini-review, we discuss some of the known and proposed mechanisms by which Tregs exert their influence in the context of immune regulation, and the contribution of mathematical modeling for these mechanistic studies. These models explore the mechanisms of action of regulatory T cells, and include hypotheses of multiple signals, delivered through simultaneous antigen-presenting cell (APC) conjugation; interaction of feedback loops between APC, Tregs, and effector cells; or production of specific cytokines that act on effector cells. As the field matures, and competing models are winnowed out, it is likely that we will be able to quantify how tolerance-inducing strategies, such as CD4-blockade, affect T-cell dynamics and what mechanisms explain the observed behavior of T-cell based tolerance.
Collapse
Affiliation(s)
- Marta Caridade
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa , Lisbon , Portugal ; Instituto Gulbenkian de Ciência , Oeiras , Portugal
| | | | | |
Collapse
|
7
|
Fu F, Lang Y, Li X, Chai Z, Tong G, Liu S, Tian H, Li H, Wang W, Chen X, Li X. Evaluation of the enhancing ability of three adjuvants for DNA vaccination using the porcine circovirus type 2 ORF2 (capsid) gene in mice. Virus Res 2012; 171:247-51. [PMID: 23123215 DOI: 10.1016/j.virusres.2012.10.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 10/20/2012] [Accepted: 10/23/2012] [Indexed: 10/27/2022]
Abstract
Molecular adjuvants were used to augment the amplitude of the immune response in many studies recently. Ubiquitin (ub), the peptide binding truncated C-terminal portion of heat shock protein 70 (hsp70c) and interleukin-2 (IL-2) are widely investigated adjuvants which have been proved to be efficient. In our study, we compared the enhancing ability of these three adjuvants based on DNA vaccination using the porcine circovirus type 2 ORF2 (capsid) gene in mice. The results of lymphocyte proliferation assay, flow cytometric analysis (FCM), antibody titer and cytokine production showed that ub conjugated plasmid induced a stronger Th1 type cellular immune response and an observably higher level of Cap-specific serum immunoglobulin G antibody compared with hsp70c or IL-2 conjugated plasmids during the period of post-immunization. Meanwhile, the ub conjugation vaccinated group elicited stronger specific immunity against PCV2 challenge than the others during most of the time of post-challenge. Thus, these data indicate that ub is a superior adjuvant for a PCV2 DNA vaccination than the hsp70c and IL-2 molecules.
Collapse
Affiliation(s)
- Fang Fu
- Division of Swine Infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, No. 427, Maduan Street, Nangang District, Harbin 150001, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
García-Martínez K, León K. Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies. Int Immunol 2012; 24:427-46. [PMID: 22371423 DOI: 10.1093/intimm/dxr120] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Several reports in the literature have drawn a complex picture of the effect of treatments aiming to modulate IL2 activity in vivo. They seem to promote indistinctly immunity or tolerance, probably depending on the specific context, dose and timing of their application. Such complexity might derives from the dual role of IL2 on T-cell dynamics. To theoretically address the latter possibility, we develop a mathematical model for helper, regulatory and memory T-cells dynamics, which account for most well-known facts relative to their relationship with IL2. We simulate the effect of three types of therapies: IL2 injections, IL2 depletion using anti-IL2 antibodies and IL2/anti-IL2 immune complexes injection. We focus in the qualitative and quantitative conditions of dose and timing for these treatments which allow them to potentate either immunity or tolerance. Our results provide reasonable explanations for the existent pre-clinical and clinical data and further provide interesting practical guidelines to optimize the future application of these types of treatments. Particularly, our results predict that: (i) Immune complexes IL2/anti-IL2 mAbs, using mAbs which block the interaction of IL2 and CD25 (the alpha chain of IL2 receptor), is the best option to potentate immunity alone or in combination with vaccines. These complexes are optimal when a 1:2 molar ratio of mAb:IL2 is used and the mAbs have the largest possible affinity; (ii) Immune complexes IL2/anti-IL2 mAbs, using mAbs which block the interaction of IL2 and CD122 (the beta chain of IL2 receptor), are the best option to reinforce preexistent natural tolerance, for instance to prevent allograft rejection. These complexes are optimal when a 1:2 molar ratio of mAb:IL2 is used and the mAbs have intermediate affinities; (iii) mAbs anti-IL2 can be successfully used alone to treat an ongoing autoimmune disorder, promoting the re-induction of tolerance. The best strategy in this therapy is to start treatment with an initially high dose of the mAbs (one capable to induce some immune suppression) and then scales down slowly the dose of mAb in subsequent applications.
Collapse
|
9
|
Zhao G, Yan R, Muleke CI, Sun Y, Xu L, Li X. Vaccination of goats with DNA vaccines encoding H11 and IL-2 induces partial protection against Haemonchus contortus infection. Vet J 2011; 191:94-100. [PMID: 21330170 DOI: 10.1016/j.tvjl.2010.12.023] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2010] [Revised: 12/16/2010] [Accepted: 12/19/2010] [Indexed: 11/25/2022]
Abstract
DNA vaccines expressing Haemonchus contortus H11 antigen with or without interleukin (IL)-2 were tested for protection against H. contortus infection in goats. Sixteen goats (8-10 months of age) were allocated into four trial groups. On days 0 and 14, group 1 was immunised with a DNA vaccine expressing H11 and IL-2 and group 2 was immunised with a DNA vaccine expressing H11 only. Group 3 was an unvaccinated positive control group challenged with H. contortus third stage larvae (L3). Group 4 was an unvaccinated negative control group that was not challenged with L3. Animals in groups 1-3 were challenged with 5000 infective H. contortus L3 14 days after the second immunisation. Transcription of H11 and IL-2 was demonstrated in muscle by reverse transcriptase-PCR 10 days after primary immunisation and translation of H11 was detected by Western blot analysis 7 days after the second immunisation. Following immunisation with a DNA vaccine expressing H11 and IL-2, high levels of specific serum immunoglobulin (Ig) G, non-specific serum IgA, mucosal IgA, CD4(+) T lymphocytes, CD8(+) T lymphocytes and B lymphocytes were produced. Following challenge with L3, cumulative mean faecal worm egg counts and worm burdens in group 1 were reduced by 56.6% and 46.7%, respectively, while corresponding reductions in group 2 were 44.8% and 38.0%. There was a small but significant difference in abomasal worm burdens in goats in groups 1 (395.3±37.6) and 2 (459.5±101.6) compared to group 3 (741.5±241.5; P<0.05). Use of a DNA vaccine expressing H11 and IL-2 conferred partial protection against Haemonchus contortus infection in goats.
Collapse
Affiliation(s)
- GuangWei Zhao
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu 210095, PR China
| | | | | | | | | | | |
Collapse
|